Empagliflozin for kidney failure, chronic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 8 Feb 2024: Trial registered, NCT06249932
  2. 13 Mar 2024: Trial started, NCT06249932

The trials

NCT05786443: Safety and Efficacy of Empagliflozin in Hemodialysis

State
Under way
Phase
Phase 2
People
60 planned
Started
31 Jan 2024
Primary completion
30 Dec 2026
Arms
Empagliflozin
Results
None posted
  1. 27 Mar 2023: Trial registered
  2. 31 Jan 2024: Trial started

NCT06249932: Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease

State
Under way
Phase
Phase 4
People
95 planned
Started
13 Mar 2024
Primary completion
31 Dec 2027
Arms
empagliflozin
Results
None posted
  1. 8 Feb 2024: Trial registered
  2. 13 Mar 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Empagliflozin 10 MG, Empagliflozin 10 MG OD, Empagliflozin 25 MG, Empagliflozin10Mg Tab, Glyxambi component empagliflozin, Jardiance, Trijardy xr component empagliflozin.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.